ΔNp63α attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial–mesenchymal transition in cervical squamous cell carcinoma

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 10621-10632

  Zhao, Weidong ^a,b,c   Wang, Huiyan ^b   Han, Xiaohui ^a   Ma, Jie ^b   Zhou, Yuanyuan ^b   Chen, Zhengzheng ^a   Zhou, Hu ^b   Xu, Hanjie ^a   Sun, Zhengwei ^a   Kong, Beihua ^c   Fang, Huiying ^d  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b Anhui Provincial Children's Hospital   (China)

^c SHANDONG UNIVERSITY   (China)

^d Anhui Vocational Institute of Population   (China)

Author keywords

Cervical squamous cell carcinoma; Epithelial mesenchymal transition; Vimentin; catenin; Np63

Indexed keywords

BETA CATENIN; MICRORNA 205; NP63ALPHA PROTEIN; PROTEIN P63; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ANTAGOMIR; CTNNB1 PROTEIN, HUMAN; HYBRID PROTEIN; ISOPROTEIN; MICRORNA; MIRN205 MICRORNA, HUMAN; RNA; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; ZEB1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIGRATION INHIBITION; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; TRANSCRIPTION REGULATION; TUMOR INVASION; UPREGULATION; UTERINE CERVIX CARCINOMA; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ADULT; ANTAGOMIRS; BETA CATENIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN ISOFORMS; RECOMBINANT FUSION PROTEINS; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; VIMENTIN; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84957656325     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4921-5     Document Type: Article

References (36)

1. Steward BW, Wild CP (Eds): World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
3. Lee MY, Shen MR. Epithelial-mesenchymal transitions in cervical carcinoma. Am J Transl Res. 2012;4(1):1–13.
4. Qureshi R, Arora H, Rizvi MA. EMT in cervical cancer: its role in tumour progression and response to therapy. Cancer Lett. 2015;356(2 Pt B):321–31.
5. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.
6. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–37.
7. Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumor Biol. 2014;35(8):7335–42.
8. Zhao W, Zhou Y, Xu H, Cheng Y, Kong B. Snail family proteins in cervical squamous carcinoma: expression and significance. Clin Invest Med. 2013;36(4):E223–33.
9. Cheng Y, Zhou Y, Jiang W, Yang X, Zhu J, Feng D, et al. Significance of E-cadherin, β-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma. Hum Pathol. 2012;43(8):1213–20.
10. Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer. 2013;13(2):136–43.
11. Yoh K, Prywes R. Pathway regulation of p63, a director of epithelial cell fate. Front Endocrinol (Lausanne). 2015;6:51.
12. Engelmann D, Pützer BM. Emerging from the shade of p53 mutants: N-terminally truncated variants of the p53 family in EMT signaling and cancer progression. Sci Signal. 2014;7(345):re9.
13. Vanbokhoven H, Melino G, Candi E, Declercq W. p63, a story of mice and men. J Invest Dermatol. 2011;131(6):1196–207.
14. Zhou Y, Xu Q, Ling B, Xiao W, Liu P. Reduced expression of ΔNp63α in cervical squamous cell carcinoma. Clin Invest Med. 2011;34(3):e184–91.
15. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012;109(38):15312–7.
16. Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, et al. The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Bio Chem. 2013;288(5):3275–88.
17. Dang TT, Esparza MA, Maine EA, Westcott JM, Pearson GW. ΔNp63α promotes breast cancer cell motility through the selective activation components of the epithelial-to-mesenchymal transition program. Cancer Res. 2015;75(18):3925–35.
18. Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol. 2010;23(2):213–24.
19. Viganò MA, Lamartine J, Testoni B, Merico D, Alotto D, Castagnoli C, et al. New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J. 2006;25(21):5105–16.
20. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell. 2006;24(4):593–602.
21. Sethi I, Romano RA, Gluck C, Smalley K, Vojtesek B, Buck MJ, et al. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues. BMC Genomics. 2015;16:584.
22. Antonini D, Russo MT, De Rosa L, Gorrese M, Del Vecchio L, Missero C. Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol. 2010;130(5):1249–57.
23. Ratovitski EA. Tumor protein p63/microRNA network in epithelial cancer cells. Curr Genomics. 2013;14(7):441–52.
24. Lin C, Li X, Zhang Y, Guo Y, Zhou J, Gao K, et al. The microRNA feedback regulation of p63 in cancer progression. Oncotarget. 2015;6(11):8434–53.
25. Shen Y, Zhou J, Li Y, Ye F, Wan X, Lu W, et al. miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. PLoS ONE. 2014;9(10), e109299.
26. Gregory PA, Bert AG, Parterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601.
27. Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014;5:5671.
28. Niu K, Shen W, Zhang Y, Zhao Y, Lu Y. miR-205 promotes motility of ovarian cancer cells via targeting ZEB1. Gene. 2015;574(2):330–6.
29. Rodríguez-Sastre MA, González-Maya L, Delgado R, Lizano M, Tsubaki G, Mohar A, et al. Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix. Gynecol Oncol. 2005;97(2):330–6.
30. Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, et al. E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol. 2011;2011:567305.
31. Howard S, Deroo T, Fujita Y, Itasaki N. A positive role of cadherin in Wnt/β-catenin signaling during epithelial-mesenchymal transition. PLoS ONE. 2011;6(8), e23899.
32. Bhagat R, Premalata CS, Shilpa V, Pallavi VR, Ramesh G, Vijay CR, et al. Altered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma. Tumor Biol. 2013;34(4):2459–68.
33. Ran J, Lin DL, Wu RF, Chen QH, Huang HP, Qiu NX, et al. ZEB1 promotes epithelial-mesenchymal transition in cervical cancer metastasis. Fertil Steril. 2015;103(6):1606–14.e1-2.
34. Chen Z, Li S, Huang K, Zhang Q, Wang J, Li X, et al. The nuclear protein expression levels of SNAI1 and ZEB1 are involved in the progression and lymph node metastasis of cervical cancer via the epithelial-mesenchymal transition pathway. Hum Pathol. 2013;44(10):2097–105.
35. Gaya JM, López-Martínez JM, Karni-Schmidt O, Bonal DM, Algaba F, Palou J, et al. ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. J Urol. 2015;193(4):1144–50.
36. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003;9(15):5501–7.